At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 19 enrolled
Drug / intervention
Diltiazem Oral Product +1 moredrug
Likely dose
Diltiazem Oral Product 60 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial
In Brief
A Phase 4 clinical trial evaluating Diltiazem Oral Product and Diltiazem Injectable Product for Atrial Fibrillation and Flutter. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The primary objective of this study is to compare the incidence of rate control (defined as: HR \<110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral immediate release diltiazem and intravenous continuous infusion diltiazem.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation and Flutter
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartJun 2018
Primary CompletionMar 2021
TodayJul 2026
First PostedMar 21, 2018
Enrollment StartJun 1, 2018
Primary CompletionMar 21, 2021
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 8.3 years ago
Interventions
Diltiazem Oral Productdrug
Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)
Diltiazem Injectable Productdrug
Diltiazem Continuous Infusion Titrated